As CBD research continues, the positive effects of cannabidiol have already been seen in a range of fields. CBD helps to improve sleep and appetite and to alleviate muscle pain, but it is also a great ally in combating psychiatric and neurological disturbances, including depression, anxiety and epilepsy.
Indeed, the first pharmacological properties of CBD emerged in the treatment of epilepsy. In 1973, a team of Brazilian researchers discovered that CBD plays an active role in reducing or inhibiting seizures in laboratory animals. By the late 1970s, the same group of researchers decided to test CBD on 16 patients with epilepsy. During the various stages of the experiment, the patients were given either CBD or a placebo in addition to the epilepsy medicine prescribed prior to testing, which had not been able to eliminate seizures. At the end of the observation period, only one out of the eight patients treated with CBD showed no signs of improvement.
From that moment on, studies in the field continued until an important milestone was reached: in June 2018, the U.S. Food and Drug Administration approved Epidiolex, the first CBD-based drug able to significantly reduce seizures in two rare forms of epilepsy, namely Lennox-Gastaut and Dravet syndromes.
Also of note are CBD’s potential benefits in combating Parkinson’s disease (PD), a long-term degenerative disorder of the central nervous system.
With their antioxidant properties and ability to activate CB2 receptors, cannabinoids have shown promising results in helping combat this disease.